Emergent BioSolutions to Release Second Quarter 2008 Financial Results and Conduct a Conference Call on August 7, 2008

Company management will host a conference call at 9:00 am Eastern on August 7, 2008 to discuss these financial results, recent business developments and the outlook for the remainder of 2008.

The conference call will be webcast and can be accessed from the Investor Relations section of the Company's website at www.emergentbiosolutions.com, under "Investors". Participants can also access the call by dialing 888.680.0892 or 617.213.4858 (international) and providing passcode 19956266.

Emergent BioSolutions is offering call participants a pre-registration option that expedites access to the call and minimizes hold times. Pre-registrants will be issued a pin number to be used when dialing into the live call which will provide quick access to the conference call by bypassing the operator upon connection. Pre-registration is not mandatory. Those who would like to take advantage of pre-registration can do so by accessing the following website:

https://www.theconferencingservice.com/prereg/key.process?key= PF9C6EMLD. (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

A replay of the teleconference will be available approximately one hour following the conclusion of the call by dialing 888/286-8010 or 617/801-6888 and using the passcode 58119499. The replay will be available through August 21. In addition, the webcast will be archived on the company's website, www.emergentbiosolutions.com, under "Investors".

The conference call, replay and webcast will be open to all interested parties.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission--to protect life. Emergent develops, manufactures and commercializes vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. The company's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. www.emergentbiosolutions.com

SOURCE: Emergent BioSolutions Inc.

Emergent BioSolutions Inc. Investors Contact: Robert G. Burrows Vice President, Investor Relations 301-795-1877 BurrowsR@ebsi.com or Media Contact: Tracey Schmitt Director, Corporate Communications 301-795-1800 SchmittT@ebsi.com